Clinical Trial Update: Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a combination of immunotherapy and an mRNA vaccine in metastatic non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Small Cell Lung Cancer

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Metastatic Non-small Cell Lung Cancer, NSCLC | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-09-27